Celldex Therapeutics
CLDX
30.43
-0.58
-1.85%
Celldex Therapeutics
US · CLDX
#2630 by market cap
Listed 1970
30.43
-0.58
-1.85%
Live - 5344 symbols - heartbeat 226s ago
· 2026-10-08 07:54
Pre-market
30.20
-0.76%
After-hours
30.51
+0.26%
- Market cap
- 2.39B
- P/E (TTM)i
- -7.00
- P/Bi
- 3.34
- EPSi
- -3.90
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on CLDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.4 percentage points.
Institutional ownership
- Held by institutions
- 110.83% +0.37pp
- Institutions
- 303 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund70.69%
Hedge Fund27.93%
VC/PE Fund7.52%
Public Company2.84%
Insurance Company0.86%
Private Company0.58%
Government Pension Fund0.39%
Individual/Insider0.24%
Top holders as of 2026-06-30
Wellington Management Group
12.15% · 9.54M sh
BlackRock
8.92% · 7.00M sh
Kynam Capital Management, LP
6.78% · 5.32M sh
T. Rowe Price Group, Inc.
5.97% · 4.69M sh
Vanguard Capital Management, LLC
5.12% · 4.02M sh
State Street Global Advisors
4.97% · 3.90M sh
FMR
4.74% · 3.72M sh
Deep Track Capital, LP
3.74% · 2.94M sh
Logos Global Management, L.P.
2.67% · 2.10M sh
Geode Capital Management, LLC
2.58% · 2.02M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 44 buys · 6 sells
| Name | Role | Stake |
|---|---|---|
| Anthony Marucci | Chief Executive Officer | 0.05% |
| Sam Martin | Senior VP, CFO, Secretary & Treasurer | 0.04% |
| Freddy Jimenez | General Counsel | 0.04% |
| Richard Wright | Chief Commercial Officer & Senior VP | 0.03% |
| Ronald Pepin | Chief Business Officer & Senior VP | 0.03% |
| Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs | 0.02% |
| Elizabeth Crowley | Chief Product Development Officer & Senior VP | 0.01% |
| Tibor Keler | Founder, Chief Scientific Officer & Executive VP | 0.01% |
| Harry Penner | Independent Director | 0.00% |
| Karen Shoos | Independent Chair of the Board of Directors | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-24 | Harry Penner | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Herbert Conrad | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | James Marino | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Ronald Pepin | Chief Business Officer & Senior VP | Other Derivative Acquisition | +20,000 | $34.09 |
| 2026-06-24 | Anthony Marucci | Chief Executive Officer | Other Derivative Acquisition | +375,000 | $34.09 |
| 2026-06-24 | Tibor Keler | Founder, Chief Scientific Officer & Executive VP | Other Derivative Acquisition | +115,000 | $34.09 |
| 2026-06-24 | Diane Young | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +57,000 | $34.09 |
| 2026-06-24 | Sarah Cavanaugh | Senior Vice President of Corporate Affairs & Administration | Other Derivative Acquisition | +95,000 | $34.09 |
| 2026-06-24 | Garry Neil | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Keith Brownlie | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Cheryl Cohen | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Elizabeth Crowley | Chief Product Development Officer & Senior VP | Other Derivative Acquisition | +100,000 | $34.09 |
| 2026-06-24 | Rita Jain | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Sam Martin | Senior VP, CFO, Secretary & Treasurer | Other Derivative Acquisition | +93,000 | $34.09 |
| 2026-06-24 | Margo Heath-Chiozzi | Senior Vice President of Regulatory Affairs | Other Derivative Acquisition | +95,000 | $34.09 |
| 2026-06-24 | Denice Torres | Independent Director | Other Derivative Acquisition | +26,000 | $34.09 |
| 2026-06-24 | Freddy Jimenez | General Counsel | Other Derivative Acquisition | +93,000 | $34.09 |
| 2026-06-24 | Teri Lawver | SVP & Chief Commercial Officer | Other Derivative Acquisition | +90,000 | $34.09 |
| 2026-01-01 | Sam Martin | Senior VP, CFO, Secretary & Treasurer | Derivative Exercise and Retained | +4,817 | $10.38 |
| 2025-12-14 | Ronald Pepin | Chief Business Officer & Senior VP | Derivative Exercise and Retained | +19,333 | $2.78–9.02 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:54:55 · For reference only, not investment advice and not tailored to your situation.